5.24
Schlusskurs vom Vortag:
$5.71
Offen:
$5.66
24-Stunden-Volumen:
5.51M
Relative Volume:
2.14
Marktkapitalisierung:
$466.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.93%
1M Leistung:
+0.38%
6M Leistung:
+49.71%
1J Leistung:
+181.72%
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATYR
Atyr Pharma Inc
|
5.24 | 501.09M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
2024-09-05 | Eingeleitet | Jefferies | Buy |
2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
2021-05-10 | Eingeleitet | Laidlaw | Buy |
2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-03-04 | Eingeleitet | ROTH Capital | Buy |
2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
2015-12-16 | Eingeleitet | Citigroup | Neutral |
2015-06-01 | Eingeleitet | Citigroup | Buy |
2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
What analysts say about aTyr Pharma Inc. stockExponential return rates - jammulinksnews.com
Is aTyr Pharma Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.
What makes aTyr Pharma Inc. stock price move sharplyFree Stock Trading Community - beatles.ru
How aTyr Pharma Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Why aTyr Pharma Inc. stock attracts strong analyst attentionProven Win Setups - Newser
Can ATyr's EFZO-FIT Data Help Patients And Investors Breathe Easier? - RTTNews
Pulmonary Sarcoidosis Market on Track for Major Expansion - openPR.com
Pulmonary Sarcoidosis Market on Track for Major Expansion by 2032, According to DelveInsight | aTyr Pharma, Kinevant Sciences, Novartis, aTyr Pharma, Novartis Pharma, Mallinckrodt - Barchart.com
Favourable Signals For aTyr Pharma: Numerous Insiders Acquired Stock - Yahoo Finance
aTyr Pharma: Insider Buys and Russell 2000 Inclusion Signal a Rare Buying Opportunity - AInvest
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying - MSN
ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell Small Cap Comp Value Index - MarketScreener
ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell 3000E Value Index - MarketScreener
Leerink Partners Sticks to Its Buy Rating for aTyr Pharma (ATYR) - The Globe and Mail
aTyr Pharma to join Russell 2000 and 3000 indexes By Investing.com - Investing.com India
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Clinical-Stage Biotech aTyr Pharma Secures Dual Russell Index Addition, Expanding Market Presence - Stock Titan
Is aTyr Pharma, Inc. technically bullish or bearish? - MarketsMojo
Kingswood Wealth Advisors LLC Sells 10,000 Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World
aTyr Pharma (ATYR) Sees Price Target Raised Amid Optimism for Ph - GuruFocus
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance
Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat
Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DE - Defense World
Atyr PHARMA (NASDAQ:ATYR) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings - Defense World
aTyr: Promising Data But Cash May Be An Issue (NASDAQ:ATYR) - Seeking Alpha
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Atyr Pharma Inc-Aktie (ATYR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):